Corporate GovernanceJun 9, 2026, 04:32 PM
MoonLake Shareholders Approve Equity Plan Amendment, Director Election
AI Summary
MoonLake Immunotherapeutics announced that its shareholders approved an amendment and restatement of the 2022 Equity Incentive Plan at the Annual Meeting, increasing the shares available for stock-based awards by 5,000,000. The amendment also includes a one-year minimum vesting requirement and extends the plan's term to June 4, 2036. Additionally, shareholders elected Spike Loy as a Class I Director, ratified Baker Tilly US, LLP as the independent auditor, and approved the advisory vote on executive compensation.
Key Highlights
- Shareholders approved an amendment to the 2022 Equity Incentive Plan.
- The plan increases Class A Ordinary Shares available for stock-based awards by 5,000,000 shares.
- The amended plan incorporates a one-year minimum vesting requirement and extends its term to June 4, 2036.
- Spike Loy was elected as the Class I Director nominee with 47,222,233 votes for.
- Baker Tilly US, LLP was ratified as the independent auditor with 61,831,463 votes for.
- The advisory vote on executive compensation was approved with 50,365,168 votes for.
Price Impact
More from MLTX